An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

<h4>Background</h4>The risk of fatal adverse events (FAEs) due to bevacizumab-based chemotherapy has not been well described; we carried out an updated meta-analysis regarding this issue.<h4>Methods</h4>An electronic search of Medline, Embase and The Cochrane Central Register...

Full description

Bibliographic Details
Main Authors:	Hongxin Huang, Yayuan Zheng, Jianhong Zhu, Jingjing Zhang, Huapu Chen, Xinggui Chen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089960&type=printable

Similar Items

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2019-01-01)

Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
by: Tingting Liu, et al.
Published: (2020-07-01)

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
by: Matthias Totzeck, et al.
Published: (2017-08-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
by: SiYao Wei, et al.
Published: (2024-07-01)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023-01-01)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
by: Chiun Hsu, et al.
Published: (2021-07-01)

Adverse Events Related to Bevacizumab and the Management Principles in Non-small Cell Lung Cancer
by: Gang CHENG, et al.
Published: (2010-06-01)

Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis
by: Saba Maleki, et al.
Published: (2024-08-01)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Jiang Y, et al.
Published: (2019-02-01)

Response to Moghimi et al. Classification of Cupping Therapy Adverse Events: An Update
by: Tamer S. Aboushanab
Published: (2021-02-01)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
by: Trygve Holmøy, et al.
Published: (2019-08-01)

Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies
by: Claudia Campani, et al.
Published: (2024-11-01)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Published: (2021-09-01)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Yao-Ning Feng, et al.
Published: (2023-06-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.
by: Pei-Yuan Zuo, et al.
Published: (2014-01-01)

Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy
by: Zhiqiang Song, et al.
Published: (2023-02-01)

Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials
by: Yi Sun, et al.
Published: (2018-01-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Statin-Associated Muscle Adverse Events : Update for clinicians
by: Maha A. Al-Mohaissen, et al.
Published: (2016-11-01)

Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
by: Jeevan Kumar, et al.
Published: (2012-01-01)

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
by: Li X, et al.
Published: (2018-09-01)

Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
by: Ning Xia, et al.
Published: (2015-01-01)

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
by: Shin S, et al.
Published: (2018-05-01)

Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
by: Takeshi Hatanaka, et al.
Published: (2024-03-01)

Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wanming He, et al.
Published: (2025-02-01)

Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
by: Heechul Nam, et al.
Published: (2023-12-01)

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
by: Ryota Tamura, et al.
Published: (2020-09-01)

Combined Application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in Experimental Glaucoma Filtration Surgery
by: Lei Zuo, et al.
Published: (2018-01-01)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2020-12-01)

Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’
by: Masatoshi Kudo, et al.
Published: (2024-05-01)

Fatal thyrocardiac event
by: Samit Kumar Khutia, et al.
Published: (2010-01-01)

P-53 IMMUNE-MEDIATED ADVERSE EVENTS FOLLOWING ATEZOLIZUMAB PLUS BEVACIZUMAB IS ASSOCIATED WITH DECREASED SURVIVAL IN PATIENTS WITH CIRRHOSIS
by: FEDERICO PIÑERO, et al.
Published: (2024-12-01)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Toshifumi Tada, et al.
Published: (2023-04-01)

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
by: Zhiwen Fu, et al.
Published: (2023-10-01)

A fatal cause of hemoptysis
by: Chen-Yi Liao, et al.
Published: (2016-01-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis
by: Huimin Chen, et al.
Published: (2023-12-01)

Clinical trials on adverse events of therapy
by: Miguel Araujo Alonso
Published: (2011-09-01)